Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: volasertib
Drug: itraconazole

First Posted Date: 2013-01-21

Last Posted Date: 2023-09-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT01772563

Locations: 🇭🇺
National Institute of Oncology, Budapest, Hungary
🇭🇺
PRA Hungary Ltd., Phase I. Clinical Pharmacology Unit, Budapest, Hungary

Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rifampicin
Drug: Nintedanib

First Posted Date: 2013-01-17

Last Posted Date: 2014-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT01770392

Locations: 🇩🇪
1199.162.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 201335 (Test)
Drug: BI 201335 (Reference)

First Posted Date: 2013-01-10

Last Posted Date: 2015-07-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT01764945

Locations: 🇩🇪
1220.46.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1026706 Placebo
Drug: BI 1026706

First Posted Date: 2013-01-08

Last Posted Date: 2019-03-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT01763333

Locations: 🇩🇪
1320.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

Phase 1

Completed

Conditions: Arthritis, Rheumatoid
Healthy

Interventions: Drug: BI 655064
Drug: Placebo matching BI 655064

First Posted Date: 2012-12-18

Last Posted Date: 2024-03-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 107

Registration Number: NCT01751776

Locations: 🇨🇿
1293.2.00028 Boehringer Ingelheim Investigational Site, Zlin, Czechia
🇨🇿
1293.2.00024 Boehringer Ingelheim Investigational Site, Uherske Hradiste, Czechia
🇨🇿
1293.2.00049 Boehringer Ingelheim Investigational Site, Olomouc, Czechia

and more 22 locations

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 207127 + faldaprevir

First Posted Date: 2012-11-30

Last Posted Date: 2016-04-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT01737996

Locations: 🇩🇪
1241.35.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany

Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: dabigatran etexilate
Drug: ticagrelor

First Posted Date: 2012-11-28

Last Posted Date: 2014-05-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01734772

Locations: 🇩🇪
1160.142.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Hyoscine butylbromide

First Posted Date: 2012-11-28

Last Posted Date: 2019-04-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01734902

Locations: 🇩🇪
202.846.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin
Drug: Empagliflozin + Linagliptin
Drug: Empagliflozin placebo + Linagliptin placebo

First Posted Date: 2012-11-28

Last Posted Date: 2016-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 607

Registration Number: NCT01734785

Locations: 🇪🇸
1275.9.34011 Boehringer Ingelheim Investigational Site, A Coruña, Spain
🇪🇸
1275.9.34009 Boehringer Ingelheim Investigational Site, Alicante, Spain
🇳🇴
1275.9.47006 Boehringer Ingelheim Investigational Site, Svelvik, Norway

and more 87 locations

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Phase 3

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 201335 (Faldaprevir)
Drug: Ribavirin (RBV)
Drug: BI 207127
Drug: Faldaprevir (BI 201335)

First Posted Date: 2012-11-26

Last Posted Date: 2016-04-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 470

Registration Number: NCT01732796

Locations: 🇺🇸
1241.20.00002 Boehringer Ingelheim Investigational Site, Chevy Chase, Maryland, United States
🇺🇸
1241.20.00012 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇨🇦
1241.20.01008 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada

and more 98 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy